The FDA's breakthrough therapy designation facilitates accelerated development and regulatory review for therapies showing ...
Scientists at the Icahn School of Medicine at Mount Sinai have developed an experimental immunotherapy that takes an ...
Early phase 1 data suggest that in vivo, off-the-shelf CAR T therapy may be feasible in multiple myeloma, offering the promise of faster, less toxic treatment without lymphodepletion while raising ...
This interview discusses how BCMA-directed CAR T-cell therapy in multiple myeloma may be more effective when administered ...
The Food and Drug Administration (FDA) has approved Breyanzi ® (lisocabtagene maraleucel; liso-cel) for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) ...
Cipla has partnered with ImmunoACT to introduce the CAR-T cell therapy 'talicabtagene autoleucel' in South Africa, Algeria, ...
Nona Biosciences ("Nona"), a global biotechnology company advancing biologics discovery through innovative technology ...
Chimeric antigen receptor natural killer (CAR-NK) cell therapy is emerging as a promising next-generation immunotherapy with the potential to overcome key limitations of current chimeric antigen ...
A next-generation, anti-CD19 enhanced CAR T-cell therapy that secretes interleukin-18 achieved a response in 81% of lymphoma patients who failed previous CAR T-cell therapy. Duration of response was 9 ...
Nona Biosciences inks agreement with Link Cell Therapies to advance CAR-T cell therapies: Cambridge, Massachusetts Monday, January 12, 2026, 11:00 Hrs [IST] Nona Biosciences (Nona ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback